Table 5. Questions related to the level of barriers among physicians toward CKD.
CKD: Chronic Kidney Disease; NSAIDs: Non-Steroidal Anti-Inflammatory Drugs
| Statements | Strongly agree | Agree | Neutral | Disagree | Strongly disagree |
| I feel comfortable: | |||||
| Making the diagnosis of CKD in my patients | 103 (24.1%) | 149 (34.9%) | 122 (28.6%) | 44 (10.3%) | 9 (2.1%) |
| Educating my patients about CKD | 143 (33.5%) | 168 (39.3%) | 83 (19.4%) | 28 (6.6%) | 5 (1.2%) |
| Managing my patients with CKD | 77 (18%) | 136 (31.9%) | 133 (31.1%) | 70 (16.4%) | 11 (2.6%) |
| Managing medication dosing in my patients with CKD | 97 (22.7%) | 115 (26.9%) | 111 (26%) | 79 (18.5%) | 25 (5.9%) |
| Avoiding nephrotoxic medications (e.g., NSAIDs) in my patients with CKD | 186 (43.6%) | 157 (36.8%) | 63 (14.8%) | 17 (4%) | 4 (0.9%) |
| Managing hypertension in my patients with CKD | 137 (32.1%) | 165 (38.6%) | 84 (19.7%) | 34 (8%) | 7 (1.6%) |
| Managing anemia of CKD in my patients | 94 (22%) | 142 (33.3%) | 129 (30.2%) | 53 (12.4%) | 9 (2.1%) |
| Managing bone disorders of CKD in my patients | 66 (15.5%) | 105 (24.6%) | 129 (30.2%) | 109 (25.5%) | 18 (4.2%) |
| Managing electrolyte disorders (e.g., hyperkalemia) in my patients with CKD | 88 (20.6%) | 110 (25.8%) | 111 (26%) | 89 (20.8%) | 29 (6.8%) |
| Managing metabolic acidosis in my patients with CKD | 71 (16.6%) | 105 (24.6%) | 96 (22.5%) | 110 (25.8%) | 45 (10.5%) |
| I have available tools (e.g., electronic medical record alerts; checklists; or printed, web-based, or smartphone-based resources) which help me to: | |||||
| Diagnose CKD | 114 (26.7%) | 145 (34%) | 95 (22.2%) | 49 (11.5%) | 24 (5.6%) |
| Manage CKD | 98 (23%) | 144 (33.7%) | 108 (25.3%) | 54 (12.6%) | 23 (5.4%) |
| Manage medication dosing | 119 (27.9%) | 156 (36.5%) | 89 (20.8%) | 43 (10.1%) | 20 (4.7%) |
| Avoid prescribing nephrotoxic medications | 115 (26.9%) | 159 (37.2%) | 91 (21.3%) | 44 (10.3%) | 18 (4.2%) |
| Manage hypertension in my patients with CKD | 107 (25.1%) | 166 (38.9%) | 97 (22.7%) | 42 (9.8%) | 15 (3.5%) |
| Manage anemia of CKD | 97 (22.7%) | 146 (34.2%) | 110 (25.8%) | 56 (13.1%) | 18 (4.2%) |
| Manage bone disorders of CKD | 79 (18.5%) | 129 (30.2%) | 123 (28.8%) | 68 (15.9%) | 28 (6.6%) |
| Manage hyperkalemia in CKD | 98 (23%) | 127 (29.7%) | 119 (27.9%) | 58 (13.6%) | 25 (5.9%) |
| Manage metabolic acidosis in CKD | 86 (20.1%) | 107 (25.1%) | 127 (29.7%) | 76 (17.8%) | 31 (7.3%) |
| I have educational tools and resources (e.g., printed and web-based materials/programs, classes, or health educators) available to help my patients understand: | |||||
| Their CKD diagnosis | 78 (18.3%) | 131 (30.7%) | 117 (27.4%) | 71 (16.6%) | 30 (7%) |
| The potential medication-related risks associated with CKD (e.g., nephrotoxins, medication dosing) | |||||
| 72 (16.9%) | 121 (28.3%) | 132 (30.9%) | 64 (15%) | 38 (8.9%) | |
| Anemia of CKD | 65 (15.2%) | 121 (28.3%) | 130 (30.4%) | 77 (18%) | 34 (8%) |
| Hypertension in CKD | 66 (15.5%) | 134 (31.4%) | 125 (29.3%) | 68 (15.9%) | 34 (8%) |
| Bone disorders in CKD patients | 58 (13.6%) | 115 (26.9%) | 127 (29.7%) | 93 (21.8%) | 34 (8%) |
| Hyperkalemia in CKD | 66 (15.5%) | 116 (27.2%) | 125 (29.3%) | 84 (19.7%) | 36 (8.4%) |
| Metabolic acidosis in CKD | 59 (13.8%) | 115 (26.9%) | 123(28.8%) | 91 (21.3%) | 39 (9.1%) |